Is a GLP-1 safe to start during perimenopause?

Key takeaways

Dr. Linda's take

The question underneath this one is usually not really about the drug. It is, "Am I too old for this, or too hormonal, or too far into the change for it to be right or safe for me?"

So let me say the plain thing first. Perimenopause is not a contraindication. It is not on any label as a reason to hold back, and approval is written around weight status, not around whether your cycles have started to shift. That does not mean the answer is automatically yes for you. It means the real questions are the same ones anyone starting these medications should ask, plus a few that matter more in your forties and fifties: your muscle and bone, your gut, your thyroid history, and whether pregnancy is still possible. A clinician weighs those with you. Below is what the evidence and the labels actually say, so you walk into that visit already knowing the map.

Is there an age or menopause limit on who can start?

No. The labels set eligibility by weight, not by life stage.

The Zepbound label indicates the medication to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. The Wegovy label indicates the medication to reduce excess body weight and maintain weight reduction long term in adults with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition.

Notice what is not in either sentence: no age cutoff, no mention of menopausal status, nothing about where you are in the transition. In the pivotal Zepbound trial, patients enrolled had obesity (BMI 30 kg/m2 or higher), or overweight (BMI 27 to under 30 kg/m2) and at least one weight-related comorbid condition. Perimenopause is a season, not a disqualifier.

There is even reason to think the response holds up in this stage. A post hoc analysis of the SURMOUNT trials found that in SURMOUNT-1, significantly greater body weight reductions were observed with tirzepatide versus placebo in women in perimenopause, at 23% versus 3%. That was a retrospective look and it measured weight, not symptoms, so read it as reassurance that midlife bodies do respond, not as a promise about your own result.

What does the label say about who should not take it?

This is where "safe to start" gets its honest answer, because the real limits are not about age at all. They apply to a person of any life stage.

Both labels carry the same boxed warning and the same hard contraindication. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Wegovy is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The label states the reason plainly. In rats, tirzepatide causes thyroid C-cell tumors, and it is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans as the human relevance of the rodent findings has not been determined. That thyroid history question does not change with menopause. It is worth raising regardless of age.

The other contraindication on both labels is a known serious hypersensitivity to the medication or any of its excipients.

Pregnancy is the other bright line, and it matters more in perimenopause than people expect, because irregular cycles do not mean fertility has ended. The Zepbound label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and advises discontinuing the medication when a pregnancy is recognized. The Wegovy label similarly states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and to discontinue Wegovy in pregnant patients who are using it for weight reduction. If pregnancy is still possible for you, that is a conversation to have before starting, not after.

What safety points matter most in perimenopause?

A few things carry extra weight in this decade.

Muscle and bone. This is the one I most want midlife women to hear, because estrogen decline is already pulling on both. Over 25% of total weight lost with these therapies typically comes from fat-free mass, including skeletal muscle mass, and loss of muscle and bone as well as anemia can compromise physical function, metabolic rate, and overall health, especially in older adults. That is not a reason to avoid treatment. It is a reason to pair it with protein and resistance training and to have muscle mass on the radar from day one. I go deeper in muscle loss in perimenopause.

The gut side. The most common adverse reactions reported in at least 5% of patients treated with Zepbound are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease. These tend to show up during dose increases and settle for most people, but in a body already navigating disrupted sleep and shifting appetite, they are worth planning around.

Interactions and contraception. If you take a pill, the two medications differ. For tirzepatide, the label states that use may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, and advises patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation. For semaglutide, no clinically significant differences in the pharmacokinetics of ethinyl estradiol or levonorgestrel were observed when used together with semaglutide. If you are also weighing hormone therapy, that overlap is covered in hormone therapy in perimenopause.

None of these is a stop sign. They are the reasons the decision belongs in a real visit rather than in a search bar. If you want a structured place to start, the Body Good quiz gathers your history so a clinician can weigh it with you.

Frequently asked questions

Does being in perimenopause make a GLP-1 unsafe to start?

Perimenopause is not listed as a contraindication on either label. The Zepbound label indicates the medication to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. Whether it is right for you still depends on your full history, which is what a clinician reviews.

What actually disqualifies someone, at any age?

The hard contraindications are the same across life stages. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A known serious hypersensitivity to the medication or any of its excipients is the other.

I still get periods sometimes. Does pregnancy risk matter here?

Yes. Irregular cycles are not the same as no fertility. The Zepbound label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and advises discontinuing the medication when a pregnancy is recognized. Contraception is worth settling before you start.

Will I lose muscle and bone at a worse time?

It is a fair concern in midlife. Over 25% of total weight lost with these therapies typically comes from fat-free mass, including skeletal muscle mass, and loss of muscle and bone as well as anemia can compromise physical function, metabolic rate, and overall health, especially in older adults. The countermove is protein and resistance training, planned from the start. More on that in perimenopause belly fat.

References

1. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-22).
2. Novo Nordisk (2026). WEGOVY (semaglutide) injection - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-22).
3. Metabolism: clinical and experimental (2024). The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. PubMed PMID 39481534. https://pubmed.ncbi.nlm.nih.gov/39481534/ (Accessed 2026-07-22).
4. Obesity (Silver Spring, Md.) (2025). Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. PubMed PMID 40074721. https://pubmed.ncbi.nlm.nih.gov/40074721/ (Accessed 2026-07-22).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-22.*